Superoxide dismutase (SOD) and glutathione (GSH) levels were remarkably enhanced, while malondialdehyde levels were reduced.[60] At the same time, it inhibits the NF-κB/NLRP3 signaling pathway by inhibiting the phosphorylation of P-65 and IκBα and blocking the expression of NLRP3, ASC, IL-1β, and Caspase-1.[60] In summary, PAL prevents MSU-induced inflammation and oxidative stress by regulating the NF-κB signaling pathway, and is a potential candidate drug for the treatment of gouty arthritis. Here, NLRP3 is linked to gout.